Xenetic Biosciences and Baxter International have amended their licensing agreement related to the development of polysialylated blood coagulation factors, including Factor VIII, using Xenetic’s technology platform. Under the amended agreement Xenetic Biosciences has received a $10 million investment from Baxter, and is eligible for increased milestone payments totaling as much as $100 million, as well as increased royalties on sales.   “We are extremely pleased by Baxter’s com...